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Molecular imaging Markers to Track 
Huntington’s Disease Pathology
Heather Wilson, Rosa De Micco, Flavia Niccolini and Marios Politis*
Neurodegeneration Imaging Group, Department of Basic and Clinical Neuroscience, King’s College London, London, UK
Huntington’s disease (HD) is a progressive, monogenic dominant neurodegenerative 
disorder caused by repeat expansion mutation in the huntingtin gene. The accumu-
lation of mutant huntingtin protein, forming intranuclear inclusions, subsequently leads 
to degeneration of medium spiny neurons in the striatum and cortical areas. Genetic 
testing can identify HD gene carriers before individuals develop overt cognitive, psy-
chiatric, and chorea symptoms. Thus, HD gene carriers can be studied in premanifest 
stages to understand and track the evolution of HD pathology. While advances have 
been made, the precise pathophysiological mechanisms underlying HD are unclear. 
Magnetic resonance imaging (MRI) and positron emission tomography (PET) have been 
employed to understand HD pathology in presymptomatic and symptomatic disease 
stages. PET imaging uses radioactive tracers to detect specific changes, at a molecular 
level, which could be used as markers of HD progression and to monitor response to 
therapeutic treatments for HD gene expansion carriers (HDGECs). This review focuses 
on available PET techniques, employed in cross-sectional and longitudinal human 
studies, as biomarkers for HD, and highlights future potential PET targets. PET studies 
have assessed changes in postsynaptic dopaminergic receptors, brain metabolism, 
microglial activation, and recently phosphodiesterase 10A (PDE10A) as markers to track 
HD progression. Alterations in PDE10A expression are the earliest biochemical change 
identified in HD gene carriers up to 43 years before predicted symptomatic onset. Thus, 
PDE10A expression could be a promising marker to track HD progression from early 
premanifest disease stages. Other PET targets which have been less well investigated 
as biomarkers include cannabinoid, adenosine, and GABA receptors. Future longitudi-
nal studies are required to fully validate these PET biomarkers for use to track disease 
progression from far-onset premanifest to manifest HD stages. PET imaging is a crucial 
neuroimaging tool, with the potential to detect early changes and validate sensitivity of 
biomarkers for tracking HD pathology. Moreover, continued development of novel PET 
tracers provides exciting opportunities to investigate new molecular targets, such as 
histamine and serotonin receptors, to further understand the mechanisms underlying 
HD pathology.
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FiguRe 1 | Changes in molecular positron emission tomography 
(PeT) biomarkers in premanifest Huntington’s disease expansion 
gene carriers (HDgeCs) compared to healthy controls (HC) as the 
disease progresses toward symptomatic onset. Axial [11C]IMA107, [11C]
MePPeP, [11C]PK11195, and [11C]raclopride PET images coregistered and 
fused to corresponding T1-weighted MRI to show changes in premanifest 
HDGECs compared to HC. Earliest loss of striatal phosphodiesterase 10A 
(PDE10A) is detectable on average 25 years before symptomatic onset, 
followed by loss of cortical cannabinoid type 1 receptor (CB1R), increased 
microglia activation, and loss of striatal dopamine type 2 receptor (D2R) 
binding. Images produced from our data.
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iNTRODuCTiON
Huntington’s disease (HD) is an inherited, neurodegenerative 
disorder caused by a CAG (codon that codes for amino acid 
glutamine) repeat expansion in the huntingtin gene (HTT) on 
chromosome 4 (1). The prevalence of HD varies by ethnic origin 
and different genetic profiles; in Caucasian populations of North 
America and Western Europe is 5.70 per 100,000 whereas in 
Asian populations is considerably lower (0.40 per 100,000) (2). 
The onset of symptoms is inversely associated with the size of 
the CAG repeat expansion and most commonly occurs at the 
age of mid-40s (3). However, subclinical changes and patho-
logical processes are thought to precede the initiation of clinical 
symptoms by several years (4–9). There is currently no cure or 
disease-modifying therapy for HD, and symptomatic treatment 
is limited. HD will eventually lead to death, typically 15–20 years 
following symptomatic onset (10).
Huntington’s disease is clinically characterized by progres-
sive motor dysfunction, cognitive decline, and psychiatric 
disturbances. Motor dysfunction can be divided into involuntary 
movements, such as chorea, and impairment of voluntary move-
ments including bradykinesia and rigidity. Chorea presents early 
in the course of the disease and is most prominent in adult-onset 
or late-onset HD. Bradykinesia and rigidity are more dominant 
in earlier-onset HD and in late stages of adult-onset HD (11, 12). 
Significant cognitive impairments are detectable in premanifest 
HD gene expansion carriers (HDGECs) 10  years or less from 
predicted symptomatic onset, with gradual cognitive decline over 
the course of the disease (9, 13).
In HD, mutant huntingtin aggregates to form intranuclear 
inclusions, which cause neuronal dysfunction and subsequent 
degeneration of GABAergic striatal medium spiny neurons 
(MSNs) and cortical neuronal loss (14). The mechanisms underly-
ing rate of progression from preclinical stages to the symptomatic 
onset are unclear. HD is potentially a good model for develop-
ment of biomarkers of direct relevance to pathogenesis, since it 
is caused by a single gene mutation. The full penetrance of HTT 
mutation in people with more than 40 CAG expansions provides 
a unique window of opportunity to examine the neurobiological 
changes as they emerge in premanifest HDGECs (before the 
development of overt symptoms) (15) and study the clinical 
course of HD through to manifest stages (after motor symptom 
onset) (16). The identification of easily obtainable, reliable, and 
robust biomarkers of HD progression is crucial for the develop-
ment and evaluation of disease-modifying treatments.
Previously, magnetic resonance imaging (MRI) techniques 
have identified structural and functional brain changes in pre-
manifest and manifest disease stages (17). The most prominent 
and consistent change in HD is progressive striatal volume loss 
occurring about 10  years before predicted symptom onset and 
progressing into manifest HD stages (6–9). Cortical volume loss 
and white-matter changes have also been reported in premanifest 
stages, 10–8 years before predicted symptom onset, which also 
extend to manifest stages (6, 18).
Positron emission tomography (PET) is a molecular imag-
ing technique for the quantitative and non-invasive imaging 
of biological functions (19, 20). The distribution and kinetic 
profiles of compounds targeting specific biological molecules 
in tissue reflect specific biological functions in the living body. 
No alternatives exist for direct evaluation of human in  vivo 
neurochemistry. Thus, PET molecular imaging provides a 
valuable tool for investigating the molecular mechanisms 
involved in disease progression (21). An ability to monitor 
the molecular markers of disease progression also has great 
attraction for novel drug development. In HD, PET studies 
have investigated changes in dopaminergic function, brain 
metabolism, neuroinflammation, phosphodiesterases, and 
cannabinoid and adenosinergic systems providing key insights 
into disease characteristics (17, 22). To date, alterations in 
phosphodiesterase 10A (PDE10A) have been identified as the 
earliest change occurring in premanifest HDGECs, with loss 
of cannabinoid receptors, loss of postsynaptic dopaminergic 
receptors, increased microglia activation, and increased glu-
cose metabolism occurring as gene carriers progress toward 
predicted symptomatic onset (Figure  1). Therefore, PET 
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imaging has the potential to monitor changes at a molecular 
level in HDGECs from early premanifest to manifest disease 
stages.
Here, we systematically review the current status of PET 
molecular imaging as a biomarker of HD pathology and disease 
progression and discuss the prospects for incorporating these 
biomarkers into future clinical trials.
MeTHODS
Search Strategy
MEDLINE, ISI Web of Science, Cochrane Library, and Scopus 
databases electronic databases were searched for articles in 
English published until 25th of June 2016. Literature from 
abstract, conference proceedings, reviews, case-reports, and 
non-humans studies were not considered as a priority asset of our 
review. Studies were identified, combining the following major 
Medical Subject Headings: “Huntington’s disease” and “PET” 
combined with text and key words (for MEDLINE as example): 
((“Huntington Disease” [MeSH Terms] OR “Huntington’s” OR 
“Huntington’s chorea” OR “chorea” [MeSH Terms] OR “hereditary 
chorea” OR “progressive chorea” OR “late onset Huntington dis-
ease” OR “juvenile Huntington disease” OR “akinetic rigid variant 
Huntington disease”) AND (“Positron-Emission Tomography” 
[MeSH Terms] OR “positron emission tomography” OR “PET”)). 
Additional eligible studies were identified screening the reference 
lists of studies included in our analysis.
inclusion Criteria
All selected titles and abstracts were independently reviewed by 
three authors (Flavia Niccolini, Heather Wilson, and Rosa de 
Micco). Studies were excluded if the title and/or abstract were not 
appropriate for the aim of the review. Full texts were subsequently 
obtained for eligible studies or when the relevance of an article 
could not be certainty excluded. Selected studies were eligible if 
they met the following criteria: (1) cross-sectional, case–control, 
or longitudinal brain PET studies including manifest or premani-
fest HDGECs; (2) published in peer-reviewed journals; and (3) 
classification as premanifest HDGECs as established by positive 
genetic test for CAG repeat and absence of motor signs based on 
the standardized total motor score (TMS) subscale (TMS = 0) of 
the Unified Huntington Disease Rating Scale (UHDRS) with a 
diagnostic confidence level of 0 (1). Reviews, case-reports, and 
non-human studies were excluded. PET measures included the 
following radioligands: [11C]SCH23390 (dopamine D1 recep-
tors); [11C]raclopride (dopamine D2 receptors), [11C]FLB457 
(dopamine D2 receptors); [15O]H2O (brain metabolism); [18F]
FDG (glucose metabolism); [11C]PK11195 (microglial activa-
tion); [11C]IMA107 (PDE10A), [18F]JNJ42259152 (PDE10A), 
[18F]MNI-659 (PDE10A); [11C]FMZ (GABA benzodiazepine 
receptor), [18F]CPFPX [adenosine A1 (A1A) receptor], and [18F]
MK9470 [cannabinoid type 1 (CB1) receptor].
ReSuLTS
A total of 44 PET studies were identified and reviewed in this 
article.
Dopaminergic System
The neurodegenerative process in HD affects the two striatal pro-
jection pathways, each with distinct MSN populations. The direct 
pathway expressing mainly dopaminergic type 1 (D1) receptors 
(23) and projecting monosynaptically to the substantia nigra 
pars reticulata and the internal segment of the globus pallidus 
(23). The indirect pathway expressing mainly dopaminergic type 
2 (D2) receptors (23) and projecting to the external segment of 
the globus pallidus (23). This leads to severe involvement of the 
postsynaptic dopaminergic system with relatively spared presyn-
aptic dopaminergic nerve terminals. Therefore, although few PET 
studies have been performed using presynaptic dopaminergic 
tracers such as [11C]βCIT (24) and [11C]DTBZ (25), postsynaptic 
molecular imaging studies have provided further insights in the 
pathophysiology of motor and cognitive features in HD, showing 
a potential role to track HD-related pathology.
Postsynaptic dopaminergic receptors have been investigated 
using [11C]SCH22390 as a marker of D1 receptors, and [11C]raclo-
pride and [11C]FLB457 as markers of D2 receptors. The densities 
of D1 and D2 receptors were significantly reduced in the striatum, 
ranging from 40% (24) to 75% (26) in manifest HDGECs and 
from 25% (27) to 50% (28) in premanifest HDGECs. Furthermore, 
longitudinal [11C]raclopride PET studies have reported annual 
rates of decline in D2 receptors from 4% (27) to 6.3% (29) and 
mean annual loss of D1 receptors of 2% (27) in premanifest 
HDGECs. In manifest stages, mean annual loss of D2 receptors of 
3% and D1 receptors of 5% has been reported (27). MRI measures 
showed significant increased rates of total brain volume atrophy 
in premanifest and manifest HDGECs (7). A longitudinal MRI 
volumetric study showed premanifest HDGECs who converted 
to manifest HDGECs had a mean annual loss of 1.35% of white 
matter, 0.28% loss of gray matter, and 2.73% loss of caudate 
volume loss (9). Therefore, compared with mean annual rates 
of decline in MRI volumetric markers, loss of D2 receptors, as 
measured with [11C]raclopride PET, could be more sensitive to 
monitor disease progression. Moreover, in premanifest HDGECs, 
[11C]raclopride binding has also been shown more sensitive as 
disease progression biomarker than glucose metabolism in a 
combined [18F]FDG and [11C]raclopride longitudinal study (29).
Several studies have also found associations between decreased 
striatal D1 and D2 receptor levels and severity of motor impair-
ment, as assessed by the UHDRS, suggesting that these imaging 
measures might be also used to stratify disease burden (27, 30). 
HD patients with rigidity showed more pronounced reduction 
of striatal D1 and D2 receptors compared to choreic HD patients 
without rigidity (31). In a combined [11C]SCH23390 and [11C]
raclopride PET study (24), decreases in striatal D1 and D2 recep-
tors correlated significantly with the duration of symptoms 
indicating that these two receptors may be reliable quantitative 
markers for monitoring disease progression. Decreased striatal 
[11C]raclopride binding was also associated with CAG repeat 
length, after correcting for age, in both premanifest and sympto-
matic HDGECs (28, 32). While CAG repeat length influenced the 
rate of striatal D2 receptor loss, the slopes of the correlations for 
premanifest were significantly different from correlation slopes 
for manifest HDGECs (32). This suggests that the rate of disease 
progression is faster during the earlier premanifest disease stages 
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and that striatal degeneration of D2 receptors in HDGECs may 
proceed in a non-linear fashion. Thus, reduction in D2 recep-
tors may be more sensitive to track disease progression in early 
premanifest stages than later in the disease.
Decreases in striatal D1 and D2 receptors have also been cor-
related with cognitive dysfunction in premanifest and manifest 
HDGECs (33). Similarly, decreased D1 and D2 receptor levels 
have been found in extra-striatal areas such as temporal (24, 34, 
35) and frontal cortices (34, 35) in manifest HDGECs compared 
to healthy controls (HC), and correlated with cognitive impair-
ment (24, 34, 35). Interestingly, cortical [11C]raclopride was 
decreased also in premanifest HDGECs suggesting that changes 
in cortical D2 receptor availability might be an early event in HD 
pathophysiology (35).
Two cross-sectional studies have investigated the extra-striatal 
expression of D2 receptors in HD (36, 37). Loss of hypothalamic 
D2 receptors in premanifest and manifest HDGECs correlated 
with increased microglial activation (36). In the hypothalamus, 
these early pathological changes could underlie the development 
of non-motor symptoms, including sleep disturbances, alterations 
in sexual behavior, and weight loss, reported in HD. Longitudinal 
studies are required to understand if hypothalamic D2 receptor 
dysfunction in early HD progressively deteriorates in advanced 
HD stages. PET with [11C]FLB457 investigated extra-striatal D2 
receptors in mild to moderate HD, showing D2 receptors in extra-
striatal regions were relatively spared; indicating D2 receptors 
outside the striatum may not be a reliable biomarker in HD (37). 
Progression of striatal and extra-striatal postsynaptic dopamin-
ergic reduction has been addressed in several longitudinal studies 
in premanifest and manifest HDGECs. In a group of 12 manifest 
HDGECs (30), [11C]raclopride binding has been evaluated at 
baseline and over a 3-year period. This study showed decreased 
binding in striatal and extra-striatal areas, including amygdala, 
temporal, and frontal cortices, in HDGECs compared to HC at 
baseline and also revealed progressive and linear deterioration of 
striatal and cortical D2 binding overtime, although no correla-
tion between changes in UHDRS motor scores and reductions in 
striatal binding was observed.
Decline in striatal and cortical dopaminergic function is 
detectable since the early asymptomatic stages of the disease. 
Dopaminergic molecular imaging might be used to predict clini-
cal course, monitor disease progression, and track HD-related 
pathology, throughout the clinical features from motor to cogni-
tive symptoms. Moreover, due to their progressive deterioration 
overtime, these values might also be proposed as potential 
biomarkers of response to novel disease-modifying and neuro-
protective treatment.
Brain Metabolism
[18F]FDG and [15O]H2O PET have been employed to assess 
regional cerebral glucose metabolism and blood flow as a marker 
of neuronal activity and synapses status in HDGECs. Cross-
sectional [18F]FDG PET studies have demonstrated that striatal 
and cortical hypometabolism are associated with motor and cog-
nitive symptoms in HDGECs (29, 38, 39). Decreases in caudate 
glucose metabolism correlated with worse bradykinesia/rigidity 
and total functional capacity, whereas putamen hypometabolism 
correlated with worse chorea, oculomotor movements, and fine 
motor coordination in 15 manifest HDGECs (40). Caudate hypo-
metabolism was also associated to cognitive decline in manifest 
HDGECs (39, 41).
[15O]H2O PET studies have shown altered patterns of brain 
activation in manifest HDGECs (42–45). During motor tasks, 
HDGECs displayed decreased activation of the striatum, its 
frontal motor projection areas, and hyperactivity of the parietal 
areas (42), and insular regions (43, 44) suggesting that impaired 
striato–thalamo–cortical network may induce a compensatory 
recruitment of additional accessory motor pathways in HD (42–
44). Moreover, during word generation tasks, manifest HDGECs 
showed decreased cerebral blood flows in the anterior cingulate 
and inferior frontal gyri and activation of the left supramarginal 
and right inferior frontal gyri (45). These findings suggest that 
HDGECs activate compensatory neuronal mechanisms in order 
to achieve word generation.
Striatal and cortical hypometabolism is an early feature of 
HD and may precede neuronal loss (46–49). Ciarmiello and 
colleagues (47) found that striatal and cortical hypometabolism 
and white-matter volume loss seen on MR imaging preceded 
gray-matter atrophy in 24 premanifest HDGECs. Moreover, 
reduced glucose levels may contribute to the time of HD onset 
(48, 49). Specifically, premanifest HDGECs who became symp-
tomatic after 5  years showed significantly lower mean glucose 
uptake in the caudate than those who did not convert, and 
this difference was independent of mutation size (48). It was 
recently shown that also putamen hypometabolism is a predic-
tor for symptomatic conversion in a cohort of 22 premanifest 
HDGECs (49). Premanifest HDGECs who phenoconverted to 
manifest HDGECs after 10 years had significant decreased [18F]
FDG uptake in the putamen at 2-year follow-up compared to 
premanifest HDGECs who did not become symptomatic (49). 
A trend for worse putaminal metabolism at 2-year follow-up was 
observed in those premanifest HDGECs closer to symptomatic 
onset as compared to premanifest HDGECs far from onset (49). 
In early stage manifest HDGECs, glucose metabolism in fronto-
temporal and parietal cortices was significantly lower in those 
with faster progression of the disease suggesting that decreased 
cortical metabolism in early manifest HDGECs is indicative of 
rapid progression (50).
A longitudinal [18F]FDG and [11C]raclopride study showed a 
non-significant 2.3% mean annualized striatal hypometabolism 
in 10 premanifest and 8 manifest HDGECs (29). These findings 
suggest that [18F]FDG PET is a less sensitive marker of disease 
progression compared to [11C]raclopride.
[18F]FDG PET network analysis has been used to identify spa-
tial covariance patterns in premanifest HDGECs (51–53). Cross-
sectional analysis of metabolic changes has shown a reproducible 
disease-related pattern able to discriminate between premanifest 
HDGECs and HC (52). This disease-related pattern consisted in 
bilateral increases in thalamic, occipital, and cerebellar glucose 
metabolism associated with bilateral decreases in striatal metabo-
lism (52). However, premanifest HDGECs did not show consistent 
changes over time, thus limiting the utility of this pattern as a net-
work biomarker of preclinical disease progression. Longitudinal 
metabolic network analysis using changes in pattern expression 
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in 12 premanifest HDGECs who were a mean of 10 years from 
symptomatic onset showed a distinct spatial covariance pattern 
associated with disease progression (53). Over a 7-year period, 
premanifest HDGECs showed a progressive decline in glucose 
metabolism in the caudate, putamen, thalamus, insula, posterior 
cingulate gyrus, prefrontal, and occipital cortices associated with 
associated with increases in the cerebellum, pons, hippocampus, 
and orbitofrontal cortex (54). Premanifest HDGECs who showed 
further increases in metabolic network activity at baseline (>2 
SD above the normal mean) had a greater risk of symptomatic 
conversion in the following 5-year period (53). This metabolic 
progression network may provide a sensitive biomarker of disease 
progression in the decade prior to symptomatic onset and may 
be used as tool to evaluate the effect of new pharmacological 
therapies aiming to slow down the progression of the disease.
Neuroinflammation and Activated 
Microglia
Microglial activation and altered immune responses likely play a 
major role in the pathogenesis of HD (55). Microglia activation 
can be measured in  vivo using PET imaging with radioligands 
selective for 18-kDa translocator protein (TSPO), which is 
expressed on the surface of activated microglial (56, 57). To-date, 
five PET studies have used the TSPO tracer [11C]PK11195 to 
assess microglial activation in HDGECs at premanifest and 
manifest stages.
Positron emission tomography with [11C]PK11195 has 
revealed significant increases in microglial activation in striatal 
and cortical regions in premanifest (58) and manifest HDGECs 
(59). Increases in striatal microglial activation of 50% in manifest 
HD correlated with severity of striatal dopamine D2 receptor 
loss, as measured by [11C]raclopride PET, and with worse motor 
symptoms (59). In premanifest HDGECs, increased microglial 
activation in the associative striatum correlated with cognitive 
dysfunction and with higher probability of symptomatic onset 
over the next 5 years (36, 58, 60). Therefore, microglial activation 
is an early event in the course of HD and is likely involved in 
subclinical disease progression. Findings from PET imaging are 
consistent with postmortem studies, showing the presence of 
activated microglial in areas of neuronal loss in HD brains (61, 
62). These results suggest over-activation and dysregulation of 
the immune response is harmful to neuronal integrity and could 
worsen neurodegeneration in HD.
In HD, mutant huntingtin protein is expressed throughout 
the body and influences dysfunction of both the central nerv-
ous system and peripheral immune cells (63, 64). Mutant 
huntingtin-induced immune activation, subsequently exacerbat-
ing neurotoxicity, could represent a direct link between immune 
activation and pathogenesis of HD (65). Increased levels of 
plasma pro-inflammatory cytokines, such as interleukin (IL)-6, 
IL-8, and tumor necrosis factor (TNF)-α, have been reported in 
premanifest and manifest HD, with levels increasing with advanc-
ing disease (65, 66). Furthermore, plasma levels of IL-1β, IL-6, 
IL-8, and TNF-α correlated with increased [11C]PK11195 binding 
in the somatosensory cortex in premanifest HDGECs who were 
more than a decade from predicted symptomatic onset (67). 
Therefore, demonstrating in vivo a direct link between peripheral 
and central immune dysfunction in HD and supporting the role 
of immune dysfunction in pathogenesis of HD. Furthermore, 
abnormal cytokine levels before symptom onset could be used a 
biomarker to track HD progression (68).
Increased immune response could occur in response to neu-
ronal death induced by mutant huntingtin toxicity and thus may 
play a protective role in HD. However, given the harmful effects 
of microglial enzymes (69) and microglia driven neurotoxic-
ity, which is exacerbated by the presence of mutant huntingtin 
protein (65, 70), increased microglial activation is likely to 
eventually exacerbate HD pathogenesis. Immune activation in 
premanifest HD stages could trigger subsequent striatal and 
cortical neurodegeneration.
Given the growing evidence for the role of microglial activa-
tion and neuroinflammation in pathophysiology of HD, it is 
important to further understand this process. Future PET imag-
ing studies will likely incorporate new second generation PET 
tracers targeting TSPO include [11C]GE180 and [11C]PBR28, [11C]
CB184 (71) that aims to overcome poor signal-to-noise ratio and 
high levels of non-specific binding associated with [11C]PK11195 
tracer (72).
Phosphodiesterase 10A
Phosphodiesterase 10A is a dual substrate enzyme that hydrolyzes 
both cyclic adenosine monophosphate (cAMP) and cyclic guano-
sine monophosphate, thus regulates cyclic nucleotide-mediated 
intracellular signaling cascades and promotes neuronal survival 
(73, 74). Cyclic nucleotide signaling plays an important role in 
signal transduction and synaptic transmission of dopaminergic, 
noradrenergic, serotonergic, and glutamatergic neurons (75, 76). 
PDE10A is most highly expressed in the striatal MSNs, where 
it modulates the cAMP/PKA/DARPP-32 signaling cascade, 
and controls the phosphorylation state and activity of many 
downstream physiological effectors including gene transcrip-
tion factors such as cAMP-response element-binding protein, 
brain derived neurotrophic factor, extracellular signal-regulated 
kinase, and various neurotransmitter receptors and voltage-gated 
ion channels. Therefore, PDE10A plays an essential role in regu-
lation of the direct and indirect striatal output pathways striatal 
output (77–79).
Phosphodiesterase 10A expression was first assessed in vivo 
in a small cohort of five manifest HDGECs using PET with [18F]
JNJ42258152, which revealed signal loss of 70.7% in the caudate 
and 62.6% loss in the putamen (80). MRI volumetric analysis 
showed manifest HDGECs had significant striatal atrophy, which 
may affect expression of this intracellular enzyme (80). Russell 
and colleagues used PET with [18F]MNI-659 to investigate 
PDE10A expression in eight early manifest and three premanifest 
HDGECs (81, 82). Loss of 47.6% in was reported in striatal and 
pallidal in the combined manifest and premanifest HD cohort. 
The three premanifest HDGECs showed intermediate decreases 
in PDE10A expression compared to manifest HDGECs (81). 
Lower striatal [18F]MNI-659 binding correlated with worse 
UHDRS motor scores, disease burden pathology, and regional 
atrophy (81). Moreover, a 1-year follow-up study revealed loss of 
[18F]MNI-659 binding of 16.6% in caudate, 6.9% in putamen, and 
6Wilson et al. Tracking HD Pathology
Frontiers in Neurology | www.frontiersin.org January 2017 | Volume 8 | Article 11
5.8% in globus pallidus (82), thus supporting the use of PDE10A 
as a biomarker to track HD progression.
Recently, our group investigated PDE10A expression using 
PET with [11C]IMA107 in 12 far-onset premanifest HDGECs 
who were on average 25  years from predicted symptomatic 
onset, clinically normal and had no volumetric brain changes 
as confirmed by MRI voxel-based morphometry and FreeSurfer 
volumetric analysis (83, 84). Striatal and pallidal [11C]IMA107 
binding was reduced by 25–33%, and a 35% increase in bind-
ing was observed in the motor thalamic nuclei in premanifest 
HDGECs compared to HC (83). Connectivity-based functional 
parcellation analysis was carried out according to cortical–striatal 
connectivity, and striatal connectivity with substantia nigral/glo-
bus pallidus internus (striatonigral: direct pathway) and globus 
pallidus externus (striatal–pallidal: indirect pathway). Prominent 
PDE10A decreases were confined to the sensorimotor striatum 
and to the striatonigral and striatopallidal projection segments 
(83). Furthermore, the ratio between higher PDE10A expres-
sion in motor thalamic nuclei and lower PDE10A expression 
in striatopallidal projecting striatum was strongly associated 
with higher probability of symptomatic conversion in far-onset 
premanifest HDGECs (83). Loss of PDE10A expression was also 
observed beyond the basal ganglia, specifically in the insula and 
occipital cortex which are affected even at the earliest stages of 
the disease and could play a role in the development of cogni-
tive and behavioral symptoms in HD (84). Together, findings 
suggest bidirectional alterations of PDE10A signaling, within 
neuropathological salient networks, are an early biochemical 
change occurring up to 43  years before predict symptomatic 
onset of HD.
Recently, two genetic studies investigated PDE10A expression 
in patients with young onset hyperkinetic movement disorders 
who carry PDE10A mutations. A [11C]IMA107 PET study 
revealed a significant 70% loss of striatal PDE10A expression 
in an individual with biallelic PDE10A missense mutations 
(85). The second study identified three childhood-onset chorea 
patients who carried de novo heterozygous mutations in PDE10A 
(86). Substitution mutations were located in regulatory GAF-B 
domain, which binds to cAMP stimulating the activity of PDE10A 
catalytic domain. In vitro functional studies demonstrated substi-
tution mutations did not affect striatal PDE10A activity but rather 
disrupts the stimulatory effect mediated by cAMP binding to the 
GAF-B domain (86). These findings confirm that PDE10A, and 
cAMP signaling, plays a crucial role in regulating striato-cortical 
movement control. Moreover, genetic depletion of PDE10A alters 
cyclic nucleotide signaling, resulting in over-activation of motor 
activity and a hyperkinetic movement disorder. The identification 
of PDE10A mutations as a cause of chorea further highlights the 
role of PDE10A in pathogenesis of HD and motivates longitu-
dinal studies validating PDE10A as a marker to track disease 
progression.
Phosphodiesterase 10A is a promising biomarker of HD pathol-
ogy with the potential to be used to monitor disease progression 
and responses to therapeutic treatments. Large scale longitudinal 
studies are required to confirm the relationship between PDE10A 
expression levels and clinical symptomatology and validate use of 
PDE10A and [11C]IMA107 as a marker to track HD pathology.
Cannabinoid System
Cannabinoid type 1 (CB1) receptors are highly expressed on 
GABAergic striatal MSNs where they modulate synaptic trans-
mission and thus play a key role in the pathogenesis of HD (87). 
CB1 receptor signaling modulates corticostriatal depression 
of glutamatergic synaptic transmission (88), and cerebellar 
long-term depression thus facilitating inhibition of GABAergic 
inhibitory postsynaptic currents (89). CB1 receptor messenger-
RNA is one of the most consistently decreased transcripts in 
postmortem striatal tissue (90). CB1 receptor dysfunction could 
result in mutilation of CB1 receptor-dependent synaptic plasticity, 
subsequent loss of anti-GABAergic and anti-glutamatergic effect, 
loss of buffering excitotoxicity and thus, neuronal injury (91).
A PET study with [18F]MK-9470 demonstrated significant 
decreases in striatal CB1 receptor levels in 20 manifest HDGECs 
compared to HC (92). CB1 receptors likely play a central role in 
pathophysiological mechanisms underlying HD; however, it is 
unclear how early changes occur and their progression across dis-
ease stages. Future longitudinal studies should focus to use PET 
tracers specific for CB1 receptor expression, for example, [11C]
MePPEP (93), to track changes in early premanifest to advanced 
manifest HD stages, and assess associations with disease burden 
scores and clinical measures.
Adenosinergic System
Type 1 adenosine (A1) receptors are expressed through the 
human brain where they could play a neuroprotective role in 
pathological conditions such as excitotoxicity and inflammation 
(94). A PET study with [18F]CPFPX, a marker of A1 receptors, 
demonstrated a 25% loss of binding in the caudate of eight 
manifest HDGECs but no significant differences in caudate or 
putamen A1 receptor levels in premanifest HDGECs compared 
to HC (95). Increased thalamic A1 receptor levels were reported 
in far-onset premanifest HDGECs, but no change in thalamic 
receptor binding in near-onset premanifest HDGECs compared 
to HC (95). Furthermore, there was a strong correlation between 
A1 receptor binding and years to symptomatic onset. These 
findings suggest A1 receptors could shift from supranormal to 
subnormal levels during phenoconversion of HD. Differential 
regulation of A1 receptors may play a role in the pathophysiology 
of altered energy metabolism.
Other PeT Molecular Markers
Opioid and GABA receptors are also affected in HD (96). PET 
with [11C]diprenorphine, a marker of opioid receptors, has shown 
loss of 31% in the caudate and 26% loss in the putamen of five 
manifest HDGECs (43, 44). Loss of striatal opioid receptors is 
lower than striatal dopaminergic degeneration, which shows 
about 60% loss in manifest HD (31). Therefore, suggesting that 
opioid receptors are less vulnerable to disease progression and 
that dopaminergic degeneration is likely a stronger marker for 
disease progression.
Two PET studies have investigated GABA receptors in HD 
using [11C]flumazenil. In six manifest HDGECs, significant 17% 
loss of GABA receptors was reported in the caudate but not in the 
putamen or thalamus (97). Additionally, reductions in glucose 
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uptake, measured with [18F]FDG, were observed in caudate, 
putamen, and thalamus in manifest HDGECs (97). A second PET 
study found similar results with reduction in GABA receptors in 
the caudate, but not putamen, and decreased glucose uptake in 
the caudate, putamen, and thalamus in HDGECs (98). Metabolic 
changes in the putamen and thalamus, without detectable reduc-
tions of GABA receptor levels suggest that metabolic impairment 
occurs before alterations in GABA receptors and thus is likely an 
earlier marker of disease pathology. Comparing also with [11C]
raclopride binding, manifest HDGECs (who exhibited loss of D2 
receptors) showed significantly less GABA receptors in caudate 
compared to premanifest HDGECs with normal D2 receptor 
levels, whereas premanifest HDGECs with reduced D2 recep-
tors levels did not show any differences compared to manifest 
HDGECs (98). Therefore, suggesting loss of GABA receptors 
likely occurs only in manifest HD stages.
Conclusion and Future Directions
Cross-sectional and small longitudinal PET studies have 
investigated the use of dopamine receptors, brain metabolism, 
microglial activation, and PDE10A as potential HD biomark-
ers. Overall, findings indicate brain metabolic changes may be 
a sensitive marker for disease progression in premanifest stages 
and could also be predictive of symptomatic conversion in HD. 
However, longitudinal studies revealed no changes in glucose 
metabolism; thus only metabolic network analysis could be useful 
for tracking disease progression. Moreover, glucose metabolism 
has been shown to be a less sensitive marker of disease progres-
sion compared to [11C]raclopride. To-date, alterations in PDE10A 
expression are the earliest biochemical change identified in HD 
and show promising results as a biomarker to track HD pathology. 
Large longitudinal studies are required to fully validate the use of 
PDE10A compared to other molecular markers to track disease 
progression in HD. Integrated PET and MRI studies directly 
comparing PET and MRI markers are required to fully determine 
which biomarkers prove to be most sensitive for monitoring HD 
progression. It is possible that a combination of different imag-
ing markers could be more useful to track pathology at different 
disease stages (Figure 2).
There are limitations for use of the currently available bio-
markers due to some inconsistent findings over longitudinal 
studies and specific limitation described of each ligand. While 
inflammation likely plays an important role in the pathophysi-
ology of HD, microglial activation alone it is unlikely to act as 
reliable marker to track HD progression. There are a number 
of potential issues surrounding the use of immune changes as a 
marker to monitoring disease progression. These include the non-
specificity of biomarkers, other factors contributing to increased 
immune responses such as other illnesses, nutritional, metabolic, 
and infective pathology, and variability in inflammation levels 
throughout the same day or over different days making reliable 
quantification and accurate comparisons challenging. However, 
the fact that mutant huntingtin is sufficient to influence abnormal 
activation of immune responses and changes are observed prior 
FiguRe 2 | imaging biomarkers to track Huntington’s disease (HD) pathology from premanifest to symptomatic disease stages. Graphical illustration of 
current biomarkers which have been assessed to track HD progression, from premanifest to symptomatic stages, using magnetic resonance imaging (MRI) and 
positron emission tomography (PET) molecular imaging techniques. Changes in markers are representative of alterations observed in MRI and PET studies, and the 
predicted progression over the disease course. Green lines represent MRI markers (99): loss of cortical gray matter (top, dark green), cortical white matter (middle, 
green), and striatal volume (bottom, light green). Blue, red, and yellow lines represent PET markers; decline in brain metabolism (top, bright red), dopamine type 2 
(D2) receptors (bottom, dark red), cannabinoid type 1 (CB1) receptors (top, dark blue), and phosphodiesterase 10A (PDE10A) (bottom, light blue), and increased 
microglial activation (yellow).
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